Published in Am J Med on November 01, 2000
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol (2003) 2.19
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol (2004) 1.71
Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem (2008) 1.68
Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J (2012) 1.53
NRF2, cancer and calorie restriction. Oncogene (2010) 1.17
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation (2004) 1.10
Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct (2006) 1.01
Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des (2008) 0.97
Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging. Neurochem Res (2008) 0.95
Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. Aging (Albany NY) (2011) 0.95
Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry (2005) 0.93
Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res (2013) 0.91
Inhibitory effect of some tropical green leafy vegetables on key enzymes linked to Alzheimer's disease and some pro-oxidant induced lipid peroxidation in rats' brain. J Food Sci Technol (2011) 0.86
Hypoxia potentiates exocytosis and Ca2+ channels in PC12 cells via increased amyloid beta peptide formation and reactive oxygen species generation. J Physiol (2002) 0.86
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol (2005) 0.85
An investigation of the neuroprotective effects of Curcumin in a model of Homocysteine - induced oxidative stress in the rat's brain. Daru (2010) 0.85
In vitro antioxidant activity and potential inhibitory action against α-glucosidase of polysaccharides from fruit peel of tea (Camellia sinensis L.). J Zhejiang Univ Sci B (2014) 0.84
Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation (2004) 0.83
Insulin/IGF-I and related signaling pathways regulate aging in nondividing cells: from yeast to the mammalian brain. ScientificWorldJournal (2010) 0.83
Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Curr Neuropharmacol (2006) 0.83
Preventive effect of safranal against oxidative damage in aged male rat brain. Exp Anim (2014) 0.83
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. Neuropsychiatr Dis Treat (2008) 0.82
Interaction of Memantine with Homocysteine on the Apoptosis in the Rat Hippocampus cells. Int J Mol Cell Med (2012) 0.79
Therapeutic approaches to age-associated neurocognitive disorders. Dialogues Clin Neurosci (2001) 0.79
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna) (2011) 0.79
Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci (2015) 0.79
Antioxidants in the canine model of human aging. Biochim Biophys Acta (2011) 0.79
A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies. Mini Rev Med Chem (2012) 0.79
Research progress on flavonoids isolated from traditional Chinese medicine in treatment of Alzheimer's disease. Intractable Rare Dis Res (2013) 0.78
Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. Br J Pharmacol (2002) 0.78
Beta-amyloid 25-35 peptide reduces the expression of glutamine transporter SAT1 in cultured cortical neurons. Neurochem Res (2007) 0.77
Functional interaction between cyclooxygenase-2 and p53 in response to an endogenous electrophile. Redox Biol (2014) 0.76
Vanadium inhalation in a mouse model for the understanding of air-suspended particle systemic repercussion. J Biomed Biotechnol (2011) 0.76
Extra virgin olive oil modulates brain docosahexaenoic acid level and oxidative damage caused by 2,4-Dichlorophenoxyacetic acid in rats. J Food Sci Technol (2016) 0.76
Neurobiology of the aging dog. Age (Dordr) (2010) 0.76
Anticholinesterase and Antioxidative Properties of Aqueous Extract of Cola acuminata Seed In Vitro. Int J Alzheimers Dis (2014) 0.75
The effect of epicatechin on oxidative stress and mitochondrial damage induced by homocycteine using isolated rat hippocampus mitochondria. Res Pharm Sci (2017) 0.75
Oxidative toxicity in diabetes and Alzheimer's disease: mechanisms behind ROS/ RNS generation. J Biomed Sci (2017) 0.75
Hypertensive emergencies. Lancet (2000) 3.96
Insights into antibody-associated encephalitis--Bickerstaff's 1950's papers revisited. J Neurol Sci (2013) 2.13
Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke (1999) 2.12
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79
Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation (1996) 1.74
Paracetamol poisoning: the action line and the timing of acetylcysteine therapy. Ir Med J (1996) 1.40
Patients' aims for epilepsy surgery: desires beyond seizure freedom. Epilepsia (2001) 1.25
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation (1997) 1.23
Statin therapy and stroke prevention. Curr Opin Cardiol (2001) 0.92
Isolated myoclonic alien hand as the sole presentation of pathologically established Creutzfeldt-Jakob disease: a report of two patients. J Neurol Neurosurg Psychiatry (1997) 0.90
Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology (2003) 0.85
Valproate and the risk for congenital malformations: Is formulation and dosage regime important? Seizure (2012) 0.85
July 2004: 40-year-old man with headaches and dyspnea. Brain Pathol (2005) 0.85
Customer needs, expectations, and satisfaction with clinical neurophysiology services in Ireland: a case for tele-neurophysiology development. Ir Med J (2004) 0.83
The Children's Cancer and Leukaemia Group guidelines for the diagnosis and management of dysembryoplastic neuroepithelial tumours. Br J Neurosurg (2007) 0.83
Antiplatelet agents for secondary prevention of ischemic stroke. Ann Pharmacother (2001) 0.82
Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs (2001) 0.82
Imaging in patients with a first seizure. Ir Med J (2006) 0.81
Physiological formation of 8-epi-PGF2 alpha in vivo is not affected by cyclooxygenase inhibition. Adv Prostaglandin Thromboxane Leukot Res (1995) 0.81
Needs analysis for tele-neurophysiology in the Irish North-Western Health Board. Ir Med J (2004) 0.81
Use of prostacyclin (iloprost) in digital vasculitis secondary to meningococcaemia. J Neurol Neurosurg Psychiatry (2004) 0.80
Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure (2006) 0.78
Statins and cerebrovascular disease: plaque attack to prevent brain attack. Vasc Med (1999) 0.78
Elevated extracellular levels of glutamate, aspartate and gamma-aminobutyric acid within the intraoperative, spontaneously epileptiform human hippocampus. Epilepsy Res (2003) 0.78
Safety of newer generation anti-epileptic drugs in non-accidental overdose: an Irish population study. Seizure (2005) 0.77
The health care journeys experienced by people with epilepsy in Ireland: what are the implications for future service reform and development? Epilepsy Behav (2010) 0.77
Treatment of spastic dystonia with transdermal nicotine. Lancet (1997) 0.76
No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res (2008) 0.76
Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J (2003) 0.75
Formation of 8-iso-prostaglandin F2 alpha by human platelets. Agents Actions Suppl (1995) 0.75
Subcutaneous heparin during coronary thrombolysis. Too little, too late. Circulation (1992) 0.75
Nitric oxide in acute ischaemic stroke. J Neurol Neurosurg Psychiatry (2000) 0.75
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone. J Neurol Neurosurg Psychiatry (1999) 0.75
Synovial fluid polymerase chain reaction as an aid to the diagnosis of central nervous system Whipple's disease. Ann Neurol (1999) 0.75
Erythropoietin and visual hallucinations in patients on dialysis. Psychosomatics (1998) 0.75
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1998) 0.75
The language of case histories. Ann Intern Med (1998) 0.75
Felbamate in an adult population with severe refractory epilepsy. Ir Med J (2010) 0.75
An outcome analysis of seventeen patients treated surgically for intractable extratemporal epilepsy. Ir Med J (2010) 0.75
Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series. Ir Med J (2007) 0.75
Juvenile myoclonic epilepsy masquerading as ecstasy withdrawal. Ir Med J (2005) 0.75
Towards the development of integrated epilepsy services: an audit of documented epilepsy care. Ir Med J (2011) 0.75
Epilepsy care in general practice. Ir Med J (2009) 0.75
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers. J Cardiovasc Pharmacol (1999) 0.75